+ Translate

Different changes by acute electric footshock of opioid agonist and antagonist receptors in rat brain

, : Different changes by acute electric footshock of opioid agonist and antagonist receptors in rat brain. Neuroscience Letters 49(3): 307-312

Electric shock (ES) produces an opiate-like analgesia and catalepsy in rats, which may be mediated by endogenous opioid systems. The alterations of endogenous opioid receptors were investigated by an intermittent ES application. In a case of opiate agonists, [3H]dihydromorphine and [3H]D-Ala-Met-enkephalinamide, the application of ES produced a decrease of [3H]ligands' binding capacity. The binding capacity of the opiate antagonist [3H]naloxone was increased by the ES application. Endogenous putative opioid agonist- and antagonist-type receptors are differently regulated in vivo.

Accession: 005151974

PMID: 6093006

DOI: 10.1016/0304-3940(84)90307-0

Download PDF Full Text: Different changes by acute electric footshock of opioid agonist and antagonist receptors in rat brain

Submit PDF Full Text

No spam - Every submission is manually reviewed

Due to poor quality, we do not accept files from Researchgate

Submitted PDF Full Texts will always be free for everyone
(We only charge for PDFs that we need to acquire)

Select a PDF file:

Related references

Nabeshima T.; Matsuno K.; Noda Y.; Kamei H.; Kameyama T., 1985: Allosteric changes in opioid receptors induced by the electric footshock. The present electric shock (ES) schedule followed in these experiments produced different functional changes in opioid agonist, and antagonist-type receptors, depending on the type of receptor: The amount of [3H]-naloxone specific binding was incr...

Corbett, A.D.; Kosterlitz, H.W., 1986: Bremazocine is an agonist at kappa-opioid receptors and an antagonist at mu-opioid receptors in the guinea-pig myenteric plexus. The agonist and antagonist activity of bremazocine at opioid receptors in the guinea-pig myenteric plexus preparation was determined in untreated tissues and in tissues in which either mu-9 or kappa-opioid receptors were blocked preferentially. Af...

Lazar, D.F.; Medzihardsky, F., 1993: Altered transition between agonist- and antagonist-favoring states of mu-opioid receptors in brain membranes with modified microviscosity. In unmodified synaptosomal brain membranes the presence of NaCl inhibited the binding to mu receptors of the tritiated opioid agonists etorphine, Tyr-D-Ala-Gly(Me)Phe-Gly-ol, and sufentanil by 53,43, and 37%, respectively, and increased that of th...

Yoburn, B.C.; Purohit, V.; Patel, K.; Zhang, Q., 2004: Opioid agonist and antagonist treatment differentially regulates immunoreactive mu-opioid receptors and dynamin-2 in vivo. Opioid agonists and antagonists can regulate the density of mu-opioid receptors in whole animal and in cell culture. High intrinsic efficacy agonists (e.g., etorphine), but not lower intrinsic efficacy agonists (e.g., morphine), produce mu-opioid...

Portoghese, P.S.; Larson, D.L.; Sayre, L.M.; Yim, C.B.; Ronsisvalle, G.; Tam, S.W.; Takemori, A.E., 1986: Opioid agonist and antagonist bivalent ligands. The relationship between spacer length and selectivity at multiple opioid receptors. Bivalent ligands containing the oxymorphamine or naltrexamine pharmacophores connected to spacers of varying length were synthesized and evaluated for their selectivity at mu, kappa, and delta opioid receptors. The oxymorphamine bivalent ligands (...

Portoghese, P.S.; Larson, D.L.; Yim, C.B.; Sayre, L.M.; Ronsisvalle, G.; Lipkowski, A.W.; Takemori, A.E.; Rice, K.C.; Tam, S.W., 1985: Stereostructure-activity relationship of opioid agonist and antagonist bivalent ligands. Evidence for bridging between vicinal opioid receptors. Journal of Medicinal Chemistry 28(9): 1140-1141

Goldstein, A.; Naidu, A., 1990: Dextrorphan binds to opioid receptors in guinea-pig brain membranes and is an antagonist at opioid receptors in myenteric plexus. Dextrorphan (+)-tartrate, purified by repeated crystallization to remove all traces of the enantiomer levorphanol, binds to mu, delta, and kappa sites on guinea-pig brain membranes with lower affinities (by a factor of 400-3200) than levorphanol....

Lee, Y.S.; Agnes, R.S.; Hargittai, B.; Davis, P.; Ma, S.; Lai, J.; Porreca, F.; Hruby, V.J., 2001: Design and synthesis of chimeras as opioid delta/mu receptors agonist and CCKA/CCKB receptors antagonist. Abstracts of Papers American Chemical Society 221(1-2): MEDI 104

White, D.A.; Ballard, M.E.; Harmon, A.C.; Holtzman, S.G., 2008: Acute delta- and kappa-opioid agonist pretreatment potentiates opioid antagonist-induced suppression of water consumption. The primary objective of this study was to determine whether pretreatment with kappa- and delta-opioid agonists potentiates naltrexone-induced suppression of water consumption following 24 h of deprivation. This study also examined the temporal ef...

Lu, Y.; Xu, H.; Rice, K.C.; Ananthan, S.; Rothman, R.B., 2001: SoRI9409, a non-peptide opioid mu receptor agonist/delta receptor antagonist, fails to stimulate -GTP-Y-S binding at cloned opioid receptors. Recent work suggests that opioids which combine mu agonist and delta antagonist activity may be nonaddicting antinociceptive agents. SoRI9409 (5'-(4-Chlorophenyl)-17-(cyclopropylmethyl)-6,7-didehydro-3,14-dihydroxy-4,5alpha-epoxypyrido-(2&apo...